Author | Mark James Levis, MD, PhD | OncLive

Author | Mark James Levis, MD, PhD


Dr. Levis on Gilteritinib in Relapsed/Refractory FLT3-Mutated AML

September 06, 2019


Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia harboring other common co-mutations or a high FLT3-internal tandem duplication allelic ratio.